GSK-2879552
- Generic Name
- GSK-2879552
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28N2O2
- CAS Number
- 1401966-69-5
- Unique Ingredient Identifier
- GT77Z6Y09Z
Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)
Phase 1
Terminated
- Conditions
- Myelodysplastic SyndromeMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2016-10-11
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 7
- Registration Number
- NCT02929498
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2014-06-30
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 41
- Registration Number
- NCT02177812
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 29
- Registration Number
- NCT02034123
- Locations
- 🇪🇸
GSK Investigational Site, Málaga, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath